JP2020532538A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020532538A5 JP2020532538A5 JP2020512506A JP2020512506A JP2020532538A5 JP 2020532538 A5 JP2020532538 A5 JP 2020532538A5 JP 2020512506 A JP2020512506 A JP 2020512506A JP 2020512506 A JP2020512506 A JP 2020512506A JP 2020532538 A5 JP2020532538 A5 JP 2020532538A5
- Authority
- JP
- Japan
- Prior art keywords
- equation
- aliphatic
- aryl
- heteroaliphatic
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 34
- 125000001931 aliphatic group Chemical group 0.000 claims 28
- 125000003118 aryl group Chemical group 0.000 claims 27
- 125000005647 linker group Chemical group 0.000 claims 21
- 125000001072 heteroaryl group Chemical group 0.000 claims 17
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 10
- 239000010949 copper Substances 0.000 claims 10
- -1 imide esters Chemical class 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 208000005264 motor neuron disease Diseases 0.000 claims 8
- 125000005842 heteroatom Chemical group 0.000 claims 7
- 150000002431 hydrogen Chemical class 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 241000282465 Canis Species 0.000 claims 5
- 208000026072 Motor neurone disease Diseases 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 208000012902 Nervous system disease Diseases 0.000 claims 4
- 208000025966 Neurological disease Diseases 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 125000004122 cyclic group Chemical group 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 206010017065 Foster-Kennedy Syndrome Diseases 0.000 claims 3
- 206010028570 Myelopathy Diseases 0.000 claims 3
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims 3
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims 3
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims 3
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
- 230000003412 degenerative effect Effects 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 201000010901 lateral sclerosis Diseases 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 206010010957 Copper deficiency Diseases 0.000 claims 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims 2
- 108010012715 Superoxide dismutase Proteins 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 claims 2
- 150000001540 azides Chemical class 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 238000002405 diagnostic procedure Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 2
- 125000005179 haloacetyl group Chemical group 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000012948 isocyanate Substances 0.000 claims 2
- 150000002513 isocyanates Chemical class 0.000 claims 2
- 239000006210 lotion Substances 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- 229910052751 metal Inorganic materials 0.000 claims 2
- 230000002438 mitochondrial effect Effects 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 2
- 125000000213 sulfino group Chemical group [H]OS(*)=O 0.000 claims 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 150000003573 thiols Chemical class 0.000 claims 2
- 150000003923 2,5-pyrrolediones Chemical class 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000008948 Menkes Kinky Hair Syndrome Diseases 0.000 claims 1
- 208000012583 Menkes disease Diseases 0.000 claims 1
- 229910004013 NO 2 Inorganic materials 0.000 claims 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- IBAHLNWTOIHLKE-UHFFFAOYSA-N cyano cyanate Chemical compound N#COC#N IBAHLNWTOIHLKE-UHFFFAOYSA-N 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 claims 1
- 229950009041 edaravone Drugs 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 150000002527 isonitriles Chemical class 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000011987 methylation Effects 0.000 claims 1
- 238000007069 methylation reaction Methods 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 229910052759 nickel Inorganic materials 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims 1
- 238000002600 positron emission tomography Methods 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 229960004181 riluzole Drugs 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims 1
- 150000003568 thioethers Chemical class 0.000 claims 1
- 0 CCI(C(*C(*(C)C)=*1)=C)*1=C(C)C(c1ccc(C(C)C=C)cc1)=**=C(C)*C Chemical compound CCI(C(*C(*(C)C)=*1)=C)*1=C(C)C(c1ccc(C(C)C=C)cc1)=**=C(C)*C 0.000 description 24
- XDTMQSROBMDMFD-UHFFFAOYSA-N C1CCCCC1 Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- ZNKKYYNWFKHNHZ-UHFFFAOYSA-N CC1C=CC=CC1 Chemical compound CC1C=CC=CC1 ZNKKYYNWFKHNHZ-UHFFFAOYSA-N 0.000 description 1
- BRWRRWXQMCPPRZ-ROLXFIACSA-N C[C@@H]1C(CN)C1 Chemical compound C[C@@H]1C(CN)C1 BRWRRWXQMCPPRZ-ROLXFIACSA-N 0.000 description 1
- ZNKKYYNWFKHNHZ-ZETCQYMHSA-N C[C@H]1C=CC=CC1 Chemical compound C[C@H]1C=CC=CC1 ZNKKYYNWFKHNHZ-ZETCQYMHSA-N 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Cc1ccccc1 Chemical compound Cc1ccccc1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023160601A JP2024001064A (ja) | 2017-09-01 | 2023-09-25 | 治療用金属錯体およびリガンドならびにその作成および使用の方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762553714P | 2017-09-01 | 2017-09-01 | |
| US62/553,714 | 2017-09-01 | ||
| PCT/US2018/049163 WO2019046761A1 (en) | 2017-09-01 | 2018-08-31 | THERAPEUTIC METAL COMPLEXES AND LIGANDS, METHODS OF MAKING AND USING SAME |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023160601A Division JP2024001064A (ja) | 2017-09-01 | 2023-09-25 | 治療用金属錯体およびリガンドならびにその作成および使用の方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020532538A JP2020532538A (ja) | 2020-11-12 |
| JP2020532538A5 true JP2020532538A5 (enExample) | 2021-10-07 |
Family
ID=63684510
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020512506A Pending JP2020532538A (ja) | 2017-09-01 | 2018-08-31 | 治療用金属錯体およびリガンドならびにその作成および使用の方法 |
| JP2023160601A Pending JP2024001064A (ja) | 2017-09-01 | 2023-09-25 | 治療用金属錯体およびリガンドならびにその作成および使用の方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023160601A Pending JP2024001064A (ja) | 2017-09-01 | 2023-09-25 | 治療用金属錯体およびリガンドならびにその作成および使用の方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11596651B2 (enExample) |
| EP (1) | EP3676271A1 (enExample) |
| JP (2) | JP2020532538A (enExample) |
| CN (1) | CN111278835A (enExample) |
| AU (1) | AU2018325283B2 (enExample) |
| CA (1) | CA3074258A1 (enExample) |
| IL (1) | IL272895B2 (enExample) |
| WO (1) | WO2019046761A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020532538A (ja) * | 2017-09-01 | 2020-11-12 | オレゴン ステイト ユニバーシティー | 治療用金属錯体およびリガンドならびにその作成および使用の方法 |
| BR112022001301A2 (pt) * | 2019-07-25 | 2022-04-12 | Als Therapy Development Inst | Cuptsm para o tratamento de distúrbios neurodegenerativos |
| JP2023544965A (ja) | 2020-08-26 | 2023-10-26 | エイエルエス・セラピー・デヴェロップメント・インスティテュート | 神経変性障害の治療のための銅錯体 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7403524A (en) | 1959-09-15 | 1974-05-27 | Pharmaceutical compsn. - contg. alpha-dithiosemicarbazone active against trichomonas vaginalis | |
| US4107210A (en) | 1976-09-07 | 1978-08-15 | The Dow Chemical Company | Synthesis of alpha-diketones |
| CA2166676C (en) * | 1995-01-09 | 2007-05-01 | Yasuhisa Fujibayashi | Diagnostic agent for hypoxia or mitochondrial dysfunction comprising radioactive copper complex of dithiosemicarbazone derivative or diamine diol schiff base derivative |
| GB0617299D0 (en) * | 2006-09-01 | 2006-10-11 | Isis Innovation | Compounds for imaging and therapy |
| EP2099441A4 (en) | 2006-11-20 | 2010-04-28 | Univ Melbourne | METAL DISPENSER AND ITS THERAPEUTIC USES |
| AU2009326867B2 (en) * | 2008-12-12 | 2015-10-29 | The University Of Melbourne | Process for the preparation of asymmetrical bis(thiosemicarbazones) |
| ES2778038T3 (es) * | 2013-11-11 | 2020-08-07 | Collaborative Medicinal Development Llc | Complejos metálicos y métodos de tratamiento |
| WO2017070752A1 (en) * | 2015-10-29 | 2017-05-04 | The University Of Queensland | Imaging agents |
| WO2017214546A1 (en) * | 2016-06-10 | 2017-12-14 | University Of Louisville Research Foundation, Inc. | Compounds, related compositions, catalysts, electrochemical cells, fuel cells, their preparation and their uses |
| WO2018204564A1 (en) * | 2017-05-04 | 2018-11-08 | University Of Louisville Research Foundation, Inc. | Thiosemicarbazone derivatives as anti-cancer agents |
| JP2020532538A (ja) * | 2017-09-01 | 2020-11-12 | オレゴン ステイト ユニバーシティー | 治療用金属錯体およびリガンドならびにその作成および使用の方法 |
-
2018
- 2018-08-31 JP JP2020512506A patent/JP2020532538A/ja active Pending
- 2018-08-31 CN CN201880065301.9A patent/CN111278835A/zh active Pending
- 2018-08-31 CA CA3074258A patent/CA3074258A1/en active Pending
- 2018-08-31 WO PCT/US2018/049163 patent/WO2019046761A1/en not_active Ceased
- 2018-08-31 AU AU2018325283A patent/AU2018325283B2/en active Active
- 2018-08-31 EP EP18778677.7A patent/EP3676271A1/en active Pending
- 2018-08-31 IL IL272895A patent/IL272895B2/en unknown
-
2020
- 2020-02-26 US US16/802,410 patent/US11596651B2/en active Active
-
2023
- 2023-01-27 US US18/102,474 patent/US12403159B2/en active Active
- 2023-09-25 JP JP2023160601A patent/JP2024001064A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2833766B2 (ja) | アミノポリカルボン酸およびその誘導体 | |
| JP7449864B2 (ja) | エバンスブルー誘導体の化学結合体ならびに前立腺癌を標的とするための放射線療法および造影剤としてのその使用 | |
| EP0955044B1 (en) | Method of inhibiting bacterial or fungal growth using a complexing agent | |
| CN111285918B (zh) | 用于psma靶向的成像和放射疗法的金属/放射性金属标记的psma抑制物 | |
| US8623322B2 (en) | Non-invasive diagnostic agents and methods of diagnosing infectious disease | |
| JP2020532538A5 (enExample) | ||
| JP2020528889A5 (enExample) | ||
| JP2010523599A5 (enExample) | ||
| KR20110013411A (ko) | (ｆ-19)-표지된 ｌ-글루탐산 및 ｌ-글루타민 유도체 (ⅲ), 그의 용도 및 그의 수득 방법 | |
| WO1997001360A9 (en) | Compounds with chelation affinity and selectivity for first transition series elements and their use in medical therapy and diagnosis | |
| CN107847618B (zh) | Hbed-二膦酸盐/酯、其放射金属轭合物和它们作为治疗诊断剂的用途 | |
| JP6770511B2 (ja) | 心肺障害の処置のためのスフィンゴシン−１−リン酸受容体モジュレーター | |
| JP2012504131A5 (enExample) | ||
| JPH09501919A (ja) | ホスホネート部分と非ホスホネート部分との両者を有するｍｒｉ用のポリアミノ常磁性キレート | |
| EP3229848B1 (en) | Targeted contrast agents comprising a hydrazide functional group | |
| US20150291538A1 (en) | Macrocyclic Compositions And Metal Complexes For Bioimaging And Biomedical Applications | |
| JP2016514151A (ja) | ガドフォスベセット三ナトリウム一水和物の製造方法 | |
| IL272895B2 (en) | Therapeutic metal complexes and ligands and methods of making and using same | |
| KR101595324B1 (ko) | 영상화 제제로서의 ｎ-알콕시아미드 접합체 | |
| JPWO2021113524A5 (enExample) | ||
| JP5322651B2 (ja) | シンチグラフィー法 | |
| KR100778888B1 (ko) | 베타아밀로이드 펩타이드 플라크의 영상화를 위한벤질리덴아닐린 계열의 유도체 및 그의 방사성 동위원소표지화합물 | |
| TW202304469A (zh) | 酸化合物、組合物及方法 | |
| JPH0656802A (ja) | テトラアザシクロドデカン誘導体およびその用途 |